[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Idexx Laboratories (IDXX) reporting person Michael G. Erickson sold a total of 405.892 shares on 08/12/2025 in two non-derivative transactions, at prices around $649.85 to $650.00 per share. The filing shows two S-code sales: 318 shares at $649.99 and 87.892 shares at a weighted-average price of $649.8507. Following these transactions Erickson is reported to beneficially own 11,286.97 shares (the filing also lists 11,374.862 shares following the larger sale), and the filing notes 26.4960 shares previously purchased under the Issuer Employee Stock Purchase Plan.

The Form 4 was signed by an attorney-in-fact on 08/14/2025 and includes an undertaking to provide details on the number of shares sold at each price upon request. All information here is stated explicitly in the filing.

Positive

• Reporting compliance: Form 4 was filed with transaction codes, prices, and post-transaction ownership detailed and signed by attorney-in-fact.
• Continued ownership: Erickson still beneficially owns reported holdings (11,286.97 shares reported after sales).
• ESPP participation disclosed: Filing documents 26.4960 shares purchased via the Issuer Employee Stock Purchase Plan earlier in 2025.

Negative

• Insider sales: A total of 405.892 shares were sold on 08/12/2025, which could be perceived negatively by some investors.
• High sale price concentration: Shares were sold at prices ranging from $649.8492 to $650.00, indicating sales executed near a narrow high-price band.

Insights

Financial Analyst

TL;DR: Insider sold 405.892 IDXX shares at roughly $650, a routine liquidity event with limited immediate valuation impact.

The transactions are coded as sales and appear to be ordinary dispositions rather than exercises or derivative conversions. The reported sale sizes (318 and 87.892 shares) are modest in absolute terms relative to typical institutional floating supply of a large-cap like IDXX; the filing does not show any acceleration, hedging, or derivative positions tied to these sales. The disclosure of 26.4960 shares from the ESPP is informational and does not alter the characterization of these entries as ordinary sales. Impact to investors is likely neutral absent other contemporaneous material disclosures.

Corporate Governance Expert

TL;DR: Sale was properly disclosed via Form 4 and executed through counsel; documentation appears compliant with Section 16 reporting.

The Form 4 includes explicit transaction codes, prices, and post-transaction beneficial ownership figures and is signed by an attorney-in-fact, which is a common practice. The filing contains an explanatory note about ESPP purchases and offers to provide breakdowns of shares sold at different prices. There are no governance red flags in the filing itself such as late amendment language or undisclosed derivative arrangements. From a governance perspective, this is a routine insider sale disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Erickson Michael G

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		318	D	$649.99	11,374.862(1)	D
Common Stock	08/12/2025		S		87.892	D	$649.8507(2)	11,286.97	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes a total of 26.4960 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

2. Represents the weighted average price of the shares sold ranging from a low of $649.8492 to a high of $650.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Michael G. Erickson	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IDXX shares did Michael G. Erickson sell on the Form 4?

The filing reports sales totaling 405.892 shares on 08/12/2025 (318 shares and 87.892 shares).

At what price were the IDXX shares sold?

The sales were executed at prices ranging from a low of $649.8492 to a high of $650.00 per share; the weighted-average reported for one sale is $649.8507.

How many IDXX shares does Erickson beneficially own after these transactions?

The Form 4 lists post-transaction beneficial ownership figures of 11,374.862 shares after one sale and 11,286.97 shares following the subsequent sale.

Were any ESPP purchases disclosed in the filing?

Yes. The filing notes 26.4960 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

Who signed the Form 4 on behalf of the reporting person?

The form was signed by Lily J. Lu, Attorney-in-Fact for Michael G. Erickson on 08/14/2025.